|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net Income Loss | |||||
| Adjustments to profit or loss items: | |||||
| Periodic pension costs | |||||
| Depreciation expense | |||||
| Stock-based compensation | |||||
| Other income due to the termination of EF License Agreement | |||||
| Depreciation and amortization | |||||
| Gain from sale of property and equipment | |||||
| Financing expenses, net | |||||
| Theoretical wages to an interested party | |||||
| Share-based compensation expense | |||||
| Non-cash operating lease activity | |||||
| Adjustments to profit or loss items | |||||
| Changes in assets and liabilities: | |||||
| Decrease (increase) in Prepaid expenses and other accounts receivable | |||||
| Other assets | |||||
| Accounts payable | |||||
| Interest payable | |||||
| Other accrued liabilities | |||||
| Other long term liabilities | |||||
| Increase (decrease) in trade payables | |||||
| Increase (decrease) in accounts payable | |||||
| Changes in assets and liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Cash acquired in reverse acquisition | |||||
| Proceeds from sale of property and equipment | |||||
| Purchase of property and equipment | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities | |||||
| Issue of share capital and warrants (net of issuance costs) | |||||
| Proceeds from the issuance of common shares in private placement offerings | |||||
| Exercise of warrants | |||||
| Receipt of a convertible loan from shareholders | |||||
| Exercise of pre-funded warrants | |||||
| Equity issuance costs | |||||
| Proceeds from related party short term loan | |||||
| Net cash provided by financing activities | |||||
| Exchange rate differences on balances of cash, cash equivalents and restricted cash | |||||
| Increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash and cash equivalents at the beginning of period | |||||
| Cash, cash equivalents and restricted cash at the beginning of the year | |||||
| Cash, cash equivalents and restricted cash at the end of the year | |||||
| Supplemental disclosure of non-cash activities | |||||
| Conversion of shareholder loan into equity | |||||
| Accrued dividends on preferred shares | |||||
| Supplemental disclosure of cash flow information | |||||
| Cash paid during the years for taxes | |||||
| Cash paid During the year for interest | |||||
| Deferred financing costs transferred to additional paid in capital | |||||
| Issuance of preferred shares for the assumption of debt | |||||
| Issuance of common shares for debt conversion | |||||
| Issuance of common shares for conversion of preferred shares | |||||
| Change in accrued pension liability reflected in accumulated other comprehensive income | |||||
| Deemed dividend | |||||
| Reconciliation of cash, cash equivalents, and restricted cash within the Consolidated Balance Sheets to the amounts shown in the Consolidated Statements of Cash Flows above | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
| Total cash, cash equivalents, and restricted cash | |||||
Loading...